Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-25
DOI
10.3389/fonc.2020.00894
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations
- (2020) Jennifer Woyach et al. BLOOD
- BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib
- (2020) Sasanka M. Handunnetti et al. BLOOD
- Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
- (2020) Constantine S. Tam et al. BLOOD
- Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape
- (2020) Lorenzo Iovino et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
- (2019) Farrukh T. Awan et al. LEUKEMIA & LYMPHOMA
- Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab
- (2019) John C. Byrd et al. BLOOD
- IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia
- (2019) Annika Scheffold et al. BLOOD
- Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia
- (2019) Eugen Tausch et al. HAEMATOLOGICA
- Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study
- (2019) Anne Quinquenel et al. BLOOD
- Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated With Ibrutinib
- (2019) Ambrus Gángó et al. INTERNATIONAL JOURNAL OF CANCER
- State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
- (2019) Richard Lemal et al. Journal for ImmunoTherapy of Cancer
- Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics
- (2019) Anna Petrackova et al. Frontiers in Oncology
- Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
- (2019) Eliana B. Gomez et al. BLOOD
- Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
- (2019) Moritz Fürstenau et al. HAEMATOLOGICA
- Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2019) Bartosz Puła et al. Cancers
- Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
- (2019) Isha Kapoor et al. Cell Death & Disease
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Non-covalent inhibition of C481S Bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL
- (2018) Sean D. Reiff et al. BLOOD
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
- (2018) Paul M. Barr et al. HAEMATOLOGICA
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- (2018) James J. Crawford et al. JOURNAL OF MEDICINAL CHEMISTRY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?
- (2018) Benjamin L. Lampson et al. Expert Review of Hematology
- Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
- (2018) Carmen D. Herling et al. Nature Communications
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
- (2018) Paul M. Barr et al. HAEMATOLOGICA
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing–Based Oncology Assays
- (2018) Jason D. Merker et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
- (2018) Rashmi Kanagal-Shamanna et al. CANCER
- Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
- (2018) Ulrike Bacher et al. Blood Cancer Journal
- Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
- (2017) Philip A Thompson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
- (2017) Jennifer A. Woyach et al. JOURNAL OF CLINICAL ONCOLOGY
- Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
- (2017) Lawrence J. Jennings et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
- (2017) V K Patel et al. LEUKEMIA
- PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
- (2017) D Jones et al. LEUKEMIA
- Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
- (2017) J Deng et al. LEUKEMIA
- Targeting B Cell Signaling in Chronic Lymphocytic Leukemia
- (2017) Jon E. Arnason et al. Current Oncology Reports
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant
- (2016) A Hamasy et al. LEUKEMIA
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- (2016) Jan A. Burger et al. Nature Communications
- Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
- (2016) Shruti Sharma et al. Oncotarget
- Targeted therapies in CLL: mechanisms of resistance and strategies for management
- (2015) J. A. Woyach et al. BLOOD
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
- (2015) H. S. Walter et al. BLOOD
- Hypermorphic mutation of phospholipase C, 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
- (2015) T.-M. Liu et al. BLOOD
- Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
- (2015) Rossana Maffei et al. Journal of Hematology & Oncology
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
- (2015) Kami J. Maddocks et al. JAMA Oncology
- Ibrutinib inhibits BCR and NF- B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
- (2014) S. E. M. Herman et al. BLOOD
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
- (2014) S Cheng et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More